U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
Commission File Number: 000-30294
IMX PHARMACEUTICALS, INC.
-------------------------------------------------
(Name of Small Business Issuer in its Charter)
Utah 87-0394290
- ------------------------------- --------------------------
(State or Other Jurisdiction of (I.R.S. Employer
Incorporation or Organization) Identification Number)
Third Floor, 17 State Street, New York, New York 10004
- ------------------------------------------------- ----------------
(Address of Principal Executive Offices) (Zip Code)
212.509.9500
------------------------------------------------------------------------------
(Issuer's Telephone Number)
[ ] Form 10-K and Form 10-KSB [ ]Form 20-F [ ]Form 11-K
[ ] Form 10-Q and [X] Form 10-QSB
For Period Ended: September 30, 2002
[ ] Transition Report on Form 10-K
[ ] Transition Report on Form 20-F
[ ] Transition Report on Form 11-K
[ ] Transition Report on Form 10-Q
[ ] Money Market Fund Rule 30b3-1 Filing
For the Transition Period Ended: N/A
Nothing in this form shall be construed to imply that the Commission has
verified any information contained herein.
If the notification relates to a portion of the filing checked above, identify
the Items(s) to which the notification relates: N/A
Part I. Registrant Information.
The Registrant is IMX Pharmaceuticals, Inc. (the "Company") and has
an address at Third Floor, 17 State Street, New York, New York 10004.
Part II. Rules 12b-25 (b) and (c)
[X] (a) The reasons described in reasonable detail in Part III of this form
could not be eliminated without unreasonable effort or expense;
[X] (b) The subject annual report, semi-annual report, transition report on Form
10-K, Form 20-F, 11-K or Form N-SAR, or portion thereof will be filed on or
before the fifteenth calendar day following the prescribed due date; or the
subject quarterly report or transition report on Form 10-Q, or portion thereof
will be filed on or before the fifth calendar day following the prescribed due
date; and
[ ] (c) The accountant's statement or other exhibit required by Rule 12b-25(c)
has been attached if applicable.
Part III. Narrative
The Company's Form 10-QSB for the quarter ended September 30, 2002 could not be
filed within the prescribed period because the Company was unable to ascertain
certain allocations of expense and accrual of deferred income from a major
subsidiary. This information is necessary to assure an accurate report on the
internal financial aspects of the Company. This problem could not have been
eliminated by the registrant without unreasonable effort or expense.
Part IV. Other Information
(1) Name and telephone number of person to contact in regard to this
notification: Adrian Stecyk (212) 509-9500
(2) Have all other periodic reports required under section 13 or 15(d) of the
Securities Exchange Act of 1934 or section 30 of the Investment Company Act of
1940 during the preceding 12 months or for such shorter period that the
registrant was required to file such report(s) been filed? If the answer is no,
identify report(s). [ ] Yes [X] No
The financials required by Item 7 of the Form 8-K initially filed on February
15, 2002 were filed late.
(3) Is it anticipated that any significant change in results of operations from
the corresponding period for the last fiscal year will be reflected by the
earnings to be included in the subject report or portion thereof? [X] Yes [ ] No
If so, attach an explanation of the anticipated change, both narratively and
quantitatively, and, if appropriate, state the reasons why a reasonable estimate
of the results cannot be made.
IMX's consolidated revenue increased over 46% during the last quarter
as compared with the same period in 2001. The Company's consolidated net loss
for the quarter was reduced to about $(660,000) from about $(1,920,000) during
the quarter ended September 30, 2001.
In accordance with the requirements of the Securities Exchange Act of
1934, the registrant has caused this notification on Form 12b-25 to be signed in
its behalf by the undersigned thereunto duly authorized on the 14th day of
November 2002.
IMX PHARMACEUTICALS, INC.
By: /s/ Adrian Stecyk
------------------------------------
Adrian Stecyk. President